Of the, the 1088 MAb was the most potent, with an IC50 in the same order of magnitude as the positive control antibodies directed to the V3 domain name (1026) and the CD4 binding site (b12)

  • Post author:
  • Post category:cMET

Of the, the 1088 MAb was the most potent, with an IC50 in the same order of magnitude as the positive control antibodies directed to the V3 domain name (1026)…

Continue ReadingOf the, the 1088 MAb was the most potent, with an IC50 in the same order of magnitude as the positive control antibodies directed to the V3 domain name (1026) and the CD4 binding site (b12)

More information is necessary through the authors Chacra 2017 MethodsThis was a randomised, placebo\controlled, parallel\group, double\blind, multicentre, multinational study

  • Post author:
  • Post category:cMET

More information is necessary through the authors Chacra 2017 MethodsThis was a randomised, placebo\controlled, parallel\group, double\blind, multicentre, multinational study. (RCTs) and quasi\RCTs taking a look at mind\to\mind comparisons of energetic…

Continue ReadingMore information is necessary through the authors Chacra 2017 MethodsThis was a randomised, placebo\controlled, parallel\group, double\blind, multicentre, multinational study